drugset / Trial / NCT01011972
A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
XMT-1107 has been shown in nonclinical studies to slow the growth of tumors. These effects may result from blocking the growth of new blood vessels that help the tumors survive.
Timeline
- Start
- 2010-03
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XMT-1107 | Unknown | 6 mg/m2 | Intravenous |
| Subject | XMT-1107 | Unknown | 24 mg/m2 | Intravenous |
| Subject | XMT-1107 | Unknown | 40 mg/m2 | Intravenous |
| Subject | XMT-1107 | Unknown | 60 mg/m2 | Intravenous |
| Subject | XMT-1107 | Unknown | 80 mg/m2 | Intravenous |